Connecticut-based biopharmaceutical company SpringWorks Therapeutics, Inc. has established itself as a leading player in the development and commercialization of life-saving medicines for underserved patient populations affected by rare diseases and cancer. Notably, the company's groundbreaking product candidate, nirogacestat, an oral small molecule gamma secretase inhibitor, is currently undergoing Phase III DeFi trial for the treatment of desmoid tumors. SpringWorks Therapeutics is also making strides in the development of mirdametinib, an oral small molecule MEK inhibitor, which is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN. The company's portfolio includes the development of BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. SpringWorks Therapeutics has established partnerships and collaborations with leading players in the industry such as BeiGene, Ltd., GlaxoSmithKline LLC, Pfizer Inc., the Katholieke Universiteit Leuven, the Flanders Institute for Biotechnology, and the Dana-Farber Cancer Institute for the development of a portfolio of novel small molecule inhibitors. Founded in 2017, SpringWorks Therapeutics has quickly established itself as a leading force in the field of biopharmaceutical development with a clear mission of providing ground-breaking medicines to treat rare diseases and cancers.
SpringWorks Therapeutics, Inc.'s ticker is SWTX
The company's shares trade on the NASDAQ stock exchange
They are based in Stamford, Connecticut
There are 51-200 employees working at SpringWorks Therapeutics, Inc.
It is https://www.springworkstx.com/
SpringWorks Therapeutics, Inc. is in the Healthcare sector
SpringWorks Therapeutics, Inc. is in the Biotechnology industry
The following five companies are SpringWorks Therapeutics, Inc.'s industry peers: